Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May;33(4):838-46.
doi: 10.1007/s10875-012-9856-z. Epub 2012 Dec 29.

Quantification of IgM and IgA anti-pneumococcal capsular polysaccharides by a new ELISA assay: a valuable diagnostic and prognostic tool for common variable immunodeficiency

F M Cavaliere  1 , C Milito, H Martini, M Schlesier, R Dräger, K Schütz, G Brunetti, A M Pesce, V Thon, K Warnatz, I Quinti
Affiliations

Quantification of IgM and IgA anti-pneumococcal capsular polysaccharides by a new ELISA assay: a valuable diagnostic and prognostic tool for common variable immunodeficiency

F M Cavaliere et al. J Clin Immunol. 2013 May.

Abstract

Purpose: Existing ways of assessing CVID patients at risk of pulmonary infections are not universally accepted. The need to identify additional prognostic factors allowed us to evaluate the anti-polysaccharide IgA and IgM responses in 125 CVID patients immunized with the 23-valent pneumococcal polysaccharide (PS) vaccine (Pneumovax(®)).

Methods: We used a new anti-PS23 IgM and IgA ELISA assay, which evaluates a global response to all 23 polysaccharides contained in Pneumovax(®).

Results: Anti-PS23 IgM and/or IgA antibodies were detectable in a minority of CVID patients. Antibody responses were correlated to B cell subpopulations and serum immunoglobulin concentrations. The non responders had a higher incidence of pneumonia and bronchiectasis and responders had the lowest incidence of respiratory complications.

Conclusions: This new ELISA assay allows for studying vaccine response in patients on Ig replacement therapy. This test also is an additional method of evaluation of specific antibody responses representing a valuable contribution to identify prognostic marker in CVID patients.

PubMed Disclaimer

References

    1. Blood. 2008 Jan 1;111(1):77-85 - PubMed
    1. J Immunol. 2008 Jan 15;180(2):800-8 - PubMed
    1. J Infect Dis. 2000 Oct;182(4):1139-45 - PubMed
    1. Chest. 2011 Dec;140(6):1581-1589 - PubMed
    1. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD000422 - PubMed

Publication types

MeSH terms

LinkOut - more resources